SARS-CoV-2 seroprevalence in the city of Hyderabad, India in early 2021

• Published in: IJID regions Vol. 2; pp. 1 - 7
• Main Authors: Laxmaiah, Avula, Rao, Nalam Madhusudhan, Arlappa, N., Babu, Jagjeevan, Kumar, P. Uday, Singh, Priya, Sharma, Deepak, Anumalla, V. Mahesh, Kumar, T. Santhosh, Sabarinathan, R., Kumar, M. Santhos, Ananthan, R., Basha, D. Anwar, Blessy, P.P.S., Kumar, D. Chandra, Devaraj, P., Devendra, S., Kumar, M. Mahesh, Meshram, Indrapal I., Kumar, B. Naveen, Sharma, Paras, Raghavendra, P., Raghu, P., Rao, K. Rajender, Ravindranadh, P., Kumar, B. Santosh, Sarika, G., Rao, J. Srinivasa, Surekha, M.V., Sylvia, F., Kumar, Deepak, Rao, G. Subba, Tallapaka, Karthik Bharadwaj, Sowpati, Divya Tej, Srivastava, Surabhi, Murhekar, V. Manoj, Hemalatha, Rajkumar, Mishra, Rakesh K.
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01-03-2022; Elsevier
• Subjects: Coronavirus (COVID-19) Collection; COVID-19; Hyderabad; India; SARS-CoV-2 antibody; seroprevalence; serosurveillance; SARS-CoV-2 antibody; serosurveillance; CI; CSIR; seroprevalence; SARS; CCMB; Hyderabad; India; COVID-19; ACE2; SD; NIN; GHMC; RT-PCR; ODK; SPSS; COI; ICMR
• ISSN: 2772-7076; 2772-7076
• DOI: 10.1016/j.ijregi.2021.10.009

COVID-19 emerged as a global pandemic in 2020, spreading rapidly to most parts of the world. The proportion of infected individuals in a population can be reliably estimated via serosurveillance, making it a valuable tool for planning control measures. Our serosurvey study aimed to investigate SARS-CoV-2 seroprevalence in the urban population of Hyderabad at the end of the first wave of infections.
This cross-sectional survey, conducted in January 2021 and including males and females aged 10 years and above, used multi-stage random sampling. 9363 samples were collected from 30 wards distributed over six zones of Hyderabad, and tested for antibodies against SARS-CoV-2 nucleocapsid antigen.
Overall seropositivity was 54.2%, ranging from 50% to 60% in most wards. Highest exposure appeared to be among those aged 30–39 and 50–59 years, with women showing greater seropositivity. Seropositivity increased with family size, with only marginal differences among people with varying levels of education. Seroprevalence was significantly lower among smokers. Only 11% of the survey subjects reported any COVID-19 symptoms, while 17% had appeared for COVID-19 testing.
Over half the city's population was infected within a year of onset of the pandemic. However, ∼ 46% of people remained susceptible, contributing to subsequent waves of infection.